Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data

Science Translational Medicine

Volumn 10, Issue 435, 2018, Pages

  Rifat, Dalin ^a   Prideaux, Brendan ^b   Savic, Radojka M ^c   Urbanowski, Michael E ^a   Parsons, Teresa L ^a   Luna, Brian ^d   Marzinke, Mark A ^a   Ordonez, Alvaro A ^a   DeMarco, Vincent P ^a   Jain, Sanjay K ^a   Dartois, Veronique ^b   Bishai, William R ^a   Dooley, Kelly E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; FEMALE; HUMAN; LUNG FIBROSIS; LUNG TUBERCULOSIS; MAXIMUM CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RABBIT MODEL; SPUTUM CULTURE; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; LEPORIDAE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SOLUBILITY; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RABBITS; RIFAMPIN; SOLUBILITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUBERCULOSIS;

EID: 85045112808     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aai7786     Document Type: Article

References (28)

1. WHO, Global Tuberculosis Report 2017 (World Health Organization); www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf.
2. B. Prideaux, L. E. Via, M. D. Zimmerman, S. Eum, J. Sarathy, P. O'Brien, C. Chen, F. Kaya, D. M. Weiner, P.-Y. Chen, T. Song, M. Lee, T. S. Shim, J. S. Cho, W. Kim, S. N. Cho, K. N. Olivier, C. E. Barry III, V. Dartois, The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21, 1223-1227 (2015).
3. E. A. Campbell, N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb, S. A. Darst, Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104, 901-912 (2001).
4. S. E. Dorman, R. M. Savic, S. Goldberg, J. E. Stout, N. Schluger, G. Muzanyi, J. L. Johnson, P. Nahid, E. J. Hecker, C. M. Heilig, L. Bozeman, P.-J. Feng, R. N. Moro, W. MacKenzie, K. E. Dooley, E. L. Nuermberger, A. Vernon, M. Weiner; Tuberculocis Trials Consortium, Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am. J. Respir. Crit. Care Med. 191, 333-343 (2015).
5. S. E. Dorman, S. Goldberg, J. E. Stout, G. Muzanyi, J. L. Johnson, M. Weiner, L. Bozeman, C. M. Heilig, P.-J. Feng, R. Moro, M. Narita, P. Nahid, S. Ray, E. Bates, B. Haile, E. L. Nuermberger, A. Vernon, N. W. Schluger, Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the tuberculosis trials consortium. J. Infect. Dis. 206, 1030-1040 (2012).
6. K. E. Dooley, E. E. Bliven-Sizemore, M. Weiner, Y. Lu, E. L. Nuermberger, W. C. Hubbard, E. J. Fuchs, M. T. Melia, W. J. Burman, S. E. Dorman, Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin. Pharmacol. Ther. 91, 881-888 (2012).
7. I. M. Rosenthal, M. Zhang, K. N. Williams, C. A. Peloquin, S. Tyagi, A. A. Vernon, W. R. Bishai, R. E. Chaisson, J. H. Grosset, E. L. Nuermberger, Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLOS Med. 4, e344 (2007).
8. R. M. Savic, M. Weiner, W. R. MacKenzie, M. Engle, W. C. Whitworth, J. L. Johnson, P. Nsubuga, P. Nahid, N. V. Nguyen, C. A. Peloquin, K. E. Dooley, S. E. Dorman; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention, Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Clin. Pharmacol. Ther. 102, 321-331 (2017).
9. K. Sakamoto, The pathology of Mycobacterium tuberculosis infection. Vet. Pathol. 49, 423-439 (2012).
10. A. M. Dannenberg Jr., M. Sugimoto, Liquefaction of caseous foci in tuberculosis. Am. Rev. Respir. Dis. 113, 257-259 (1976).
11. M. C. Kjellsson, L. E. Via, A. Goh, D. Weiner, K. M. Low, S. Kern, G. Pillai, C. E. Barry III, V. Dartois, Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob. Agents Chemother. 56, 446-457 (2012).
12. G. Boman, V. A. Ringberger, Binding of rifampicin by human plasma proteins. Eur. J. Clin. Pharmacol. 7, 369-373 (1974).
13. A. M. Dannenberg Jr., Stages in the pathogenesis of human and rabbit tuberculosis, in Pathogenesis of Human Pulmonary Tuberculosis (ASM Press, 2006), pp. 22-33.
14. J. M. Dickinson, D. A. Mitchison, Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am. Rev. Respir. Dis. 123, 367-371 (1981).
15. T. Gumbo, A. J. Lenaerts, D. Hanna, K. Romero, E. Nuermberger, Nonclinical models for antituberculosis drug development: A landscape analysis. J. Infect. Dis. 211, (Suppl. 3) S83-S95 (2015).
16. A. A. Ordonez, R. Tasneen, S. Pokkali, Z. Xu, P. J. Converse, M. H. Klunk, D. J. Mollura, E. L. Nuermberger, S. K. Jain, Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. Dis. Model. Mech. 9, 779-788 (2016).
17. J. Harper, C. Skerry, S. L. Davis, R. Tasneen, M. Weir, I. Kramnik, W. R. Bishai, M. G. Pomper, E. L. Nuermberger, S. K. Jain, Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205, 595-602 (2012).
18. M. Zhang, S.-Y. Li, I. M. Rosenthal, D. V. Almeida, Z. Ahmad, P. J. Converse, C. A. Peloquin, E. L. Nuermberger, J. H. Grosset, Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183, 1254-1261 (2011).
19. A. Jindani, T. S. Harrison, A. J. Nunn, P. P. J. Phillips, G. J. Churchyard, S. Charalambous, M. Hatherill, H. Geldenhuys, H. M. McIlleron, S. P. Zvada, S. Mungofa, N. A. Shah, S. Zizhou, L. Magweta, J. Shepherd, S. Nyirenda, J. H. van Dijk, H. E. Clouting, D. Coleman, A. L. E. Bateson, T. D. McHugh, P. D. Butcher, D. A. Mitchison; RIFAQUIN Trial Team, High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371, 1599-1608 (2014).
20. S. H. Gillespie, A. M. Crook, T. D. McHugh, C. M. Mendel, S. K. Meredith, S. R. Murray, F. Pappas, P. P. J. Phillips, A. J. Nunn, Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577-1587 (2014).
21. C. S. Merle, K. Fielding, O. B. Sow, M. Gninafon, M. B. Lo, T. Mthiyane, J. Odhiambo, E. Amukoye, B. Bah, F. Kassa, A. N'Diaye, R. Rustomjee, B. C. de Jong, J. Horton, C. Perronne, C. Sismanidis, O. Lapujade, P. L. Olliaro, C. Lienhardt, A four-month gatifloxacin-containing regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588-1598 (2014).
22. J. P. Sarathy, F. Zuccotto, H. Hsinpin, L. Sandberg, L. E. Via, G. A. Marriner, T. Masquelin, P. Wyatt, P. Ray, V. Dartois, Prediction of drug penetration in tuberculosis lesions. ACS Infect. Dis. 2, 552-563 (2016).
23. M.-J. Kim, H. C. Wainwright, M. Locketz, L.-G. Bekker, G. B. Walther, C. Dittrich, A. Visser, W. Wang, F.-F. Hsu, U. Wiehart, L. Tsenova, G. Kaplan, D. G. Russell, Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol. Med. 2, 258-274 (2010).
24. B. Luna, A. Kubler, C. Larsson, B. Foster, U. Bagci, D. J. Mollura, S. K. Jain, W. R. Bishai, In vivo prediction of tuberculosis-associated cavity formation in rabbits. J. Infect. Dis. 211, 481-485 (2015).
25. A. Kubler, C. Larsson, B. Luna, B. B. Andrade, E. P. Amaral, M. Urbanowski, M. Orandle, K. Bock, N. C. Ammerman, L. S. Cheung, K. Winglee, M. Halushka, J. K. Park, A. Sher, J. S. Friedland, P. T. Elkington, W. R. Bishai, Cathepsin K contributes to cavitation and collagen turnover in pulmonary tuberculosis. J. Infect. Dis. 213, 618-627 (2016).
26. S. Subbian, L. Tsenova, P. O'Brien, G. Yang, N. L. Kushner, S. Parsons, B. Peixoto, D. Fallows, G. Kaplan, Spontaneous latency in a rabbit model of pulmonary tuberculosis. Am. J. Pathol. 181, 1711-1724 (2012).
27. K. E. Dooley, R. M. Savic, J.-G. Park, Y. Cramer, R. Hafner, E. Hogg, J. Janik, M. A. Marzinke, K. Patterson, C. A. Benson, L. Hovind, S. E. Dorman, D. W. Haas; ACTG A5311 Study Team, Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob. Agents Chemother. 59, 3399-3405 (2015).
28. G. G. Nedeltchev, T. R. Raghunand, M. S. Jassal, S. Lun, Q.-J. Cheng, W. R. Bishai, Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect. Immun. 77, 598-603 (2009).